Brookline Capital Markets Weighs in on CRSP FY2026 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Brookline Capital Markets increased their FY2026 earnings per share estimates for CRISPR Therapeutics in a report released on Monday, November 2nd. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings per share of ($4.74) for the year, up from their prior estimate of ($5.63). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($4.44) per share. Brookline Capital Markets also issued estimates for CRISPR Therapeutics’ Q4 2026 earnings at ($1.17) EPS and FY2027 earnings at ($3.83) EPS.

CRSP has been the subject of several other reports. Wells Fargo & Company decreased their target price on shares of CRISPR Therapeutics from $75.00 to $70.00 and set an “equal weight” rating for the company in a research note on Wednesday. Citizens Jmp reiterated a “market outperform” rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a report on Monday, August 31st. UBS Group began coverage on shares of CRISPR Therapeutics in a research report on Thursday, October 15th. They issued a “neutral” rating and a $52.00 price objective for the company. Citigroup raised their target price on CRISPR Therapeutics from $88.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating on shares of CRISPR Therapeutics in a research report on Friday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, CRISPR Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $69.69.

CRISPR Therapeutics Trading Up 3.6%

CRSP opened at $51.78 on Thursday. The firm has a market capitalization of $5.01 billion, a P/E ratio of -10.92 and a beta of 1.92. The firm’s 50 day moving average is $53.67 and its 200-day moving average is $52.84. CRISPR Therapeutics has a 52-week low of $44.12 and a 52-week high of $63.45. The company has a quick ratio of 17.85, a current ratio of 16.21 and a debt-to-equity ratio of 0.36.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, November 2nd. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($1.06) by ($0.09). The company had revenue of $12.67 million for the quarter, compared to analyst estimates of $14.75 million. CRISPR Therapeutics had a negative return on equity of 25.59% and a negative net margin of 1,812.07%. CRISPR Therapeutics’s revenue was up 1311.1% on a year-over-year basis.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,040 shares of the stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $49.26, for a total transaction of $51,230.40. Following the transaction, the general counsel directly owned 95,857 shares in the company, valued at $4,721,915.82. This represents a 1.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Simeon George sold 14,514 shares of the firm’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $49.63, for a total transaction of $720,329.82. Following the transaction, the director directly owned 15,486 shares of the company’s stock, valued at approximately $768,570.18. This represents a 48.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 93,558 shares of company stock valued at $4,881,663. Insiders own 5.20% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Swiss National Bank raised its stake in CRISPR Therapeutics by 5.1% during the first quarter. Swiss National Bank now owns 169,700 shares of the company’s stock valued at $8,073,000 after buying an additional 8,200 shares in the last quarter. Affinity Asset Advisors LLC acquired a new position in shares of CRISPR Therapeutics in the 1st quarter worth approximately $7,136,000. KBC Group NV increased its holdings in shares of CRISPR Therapeutics by 3,999.9% in the 1st quarter. KBC Group NV now owns 116,847 shares of the company’s stock valued at $5,558,000 after acquiring an additional 113,997 shares during the last quarter. Congress Asset Management Co. raised its position in shares of CRISPR Therapeutics by 1.6% during the 3rd quarter. Congress Asset Management Co. now owns 111,230 shares of the company’s stock valued at $6,153,000 after acquiring an additional 1,777 shares in the last quarter. Finally, California State Teachers Retirement System raised its position in shares of CRISPR Therapeutics by 29.6% during the 1st quarter. California State Teachers Retirement System now owns 101,232 shares of the company’s stock valued at $4,816,000 after acquiring an additional 23,109 shares in the last quarter. 69.20% of the stock is owned by institutional investors.

More CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Citigroup raised its price target to $90 from $88 and reaffirmed a “buy” rating, signaling significant potential upside in the analyst’s view. Citigroup price target report
• Positive Sentiment: The company said it will present Phase 1/2 clinical data for zugo-cel, its investigational gene-edited CAR T therapy for relapsed or refractory large B-cell lymphoma, at the ASH meeting in December. The presentation could provide investors with a meaningful pipeline update. Zugo-cel clinical data announcement
• Neutral Sentiment: CRISPR Therapeutics appointed Siva Sakhamuri as chief technical officer. His experience in manufacturing, gene editing and commercial launches may support the company’s operations, though the appointment’s financial impact is not yet clear. Chief technical officer appointment
• Negative Sentiment: Third-quarter results fell short of expectations: the company reported a $1.15-per-share loss versus the $1.06 loss analysts expected, and revenue of $12.67 million versus a $14.75 million consensus estimate. Growing Casgevy use and sales offer a counterpoint, but the earnings shortfall may weigh on sentiment. Third-quarter results coverage
• Negative Sentiment: Brookline Capital Markets slightly lowered its projected earnings per share for 2028, 2029 and 2030, a modestly cautious revision to its long-term outlook.

About CRISPR Therapeutics

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.